Kathleen A. Rickard - 08 Apr 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Medical Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Kathleen Rickard
Issuer symbol
VRNA
Transactions as of
08 Apr 2022
Net transactions value
-$98,482
Form type
4
Filing time
12 Apr 2022, 16:05:24 UTC
Previous filing
03 Feb 2022
Next filing
03 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale $66,383 -112,800 -4.1% $0.5885* 2,606,128 08 Apr 2022 Direct F1, F2, F3
transaction VRNA Ordinary Shares Sale $32,100 -59,720 -2.3% $0.5375* 2,546,408 11 Apr 2022 Direct F1, F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.5625 to $0.6075. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
F4 The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.52 to $0.5585. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 4.
F5 Consists of (i) 1,916,968 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 239,621 ADSs); and (ii) 629,440 Ordinary Shares underlying 78,680 ADSs.